News & Events
-
October 26, 2015
Cross-Laboratory Analytical Validation of the Cardiac Biomarker NT-proANP in Rat
Vinken P, Reagan WJ, Rodriguez LA, Buck WR, Lai-Zhang J, Goeminne N, Barbacci G, Liu R, King NMP, Engle SK, Colton H. Cross-Laboratory Analytical Validation of the Cardiac Biomarker NT-proANP in Rat. Journal of Pharmacological and Toxicological Methods. 2015 Oct 26.
-
October 20, 2015
Parkinson’s UK Receives CAMD Nonprofit Organization Award
Dr. Arthur Roach, Director of Research at Parkinson’s UK accepts the first Nonprofit Organization Award from CAMD presented by Dr. Diane Stephenson, Critical Path Institute, at the annual meeting held at FDA on Oct 20th, 2015. Parkinson’s UK is recognized for their leadership in supporting the launch of a fully dedicated consortium aimed at integrating... -
October 15, 2015
Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines
Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D’Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infectious Dis. 2015;61(suppl 3):S102–18.
-
October 15, 2015
Coalition Against Major Diseases and FDA 2015 Annual Scientific Workshop
October 15, 2015 FDA White Oak Campus CO-SPONSORED BY: Critical Path Institute U.S. Food and Drug Administration Overview and Objectives The Coalition Against Major Diseases (CAMD) is a public-private-partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer’s disease... -
October 15, 2015
Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done
Schito M, Maeurer M, Kim P, Hanna D, Zumla A. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done. Clin Infectious Dis. 2015;61(suppl 3):S95–101.